129788454870781250_127Hengrui medicine: innovative medicines entered into the harvest time
Eric celecoxib, invitation of tenders will achieve sales this year Eric celecoxib, mainly used to ease the pain of osteoarthritis symptoms, as a new generation of innovative non-steroidal anti-inflammatory drug, is the company's first drug approved listing of innovation. It inherited the traditional precise celecoxib drug anti-inflammatory and analgesic effect, but no obvious side-effect of the gastrointestinal tract. In 1999, the company began to develop, after more than 10 years ofUnremitting efforts, 2011 of a superior. State class new medicine iResearch celecoxib, approved June 2011 July production by GMP certification, currently under hospital Rheumatoid HKUST bulk phase IV clinical to enhance awareness and recognition of the doctor on the coast of celecoxib. Products price Eric celecoxib on a little over Pfizer's Celebrex, we expect Eric celecoxib-passTenders in different provinces, is expected to achieve sales. Innovative drug market, ARPANET erlotinib is expected to be approved at the end after the advent of the drug company's first innovation iResearch celecoxib, other varieties of new drug will be listed. We expect: �� ARPANET for the priorities approved in last year applied for the gastric cancer, gastric cancer clinical trial, if all goes well, may be listed by the end of the year; lung cancer phase III in the group is over
tera power leveling, May go on sale by the end of the year; liver cancer phase II clinical end, entering phase III this year; second phase of breast cancer is. Peter van Eyck with best? compared to erlotinib, ARPANET for the indications of wider resistance better, broader market prospect. �� method m on behalf of registered production this year, develop five or six indications, priority finish renal cell carcinoma, nasopharyngeal carcinoma starts phase III clinical trial of this year. �� long-Effect of g-CSF report production by early next year. �� SEO gelieting clinical phase II the end of this year, into phase III clinical trial. �� In addition, this year there are new 2-3 creates new drugs enter clinical trials. Steady progress in internationalization, surgical anesthetics, rapid development of contrast agents will still be 2011 Yi Li'll Yasumichi FDA certification of the company, in the United States goes on sale, and the company will take United StatesDistributors of cooperation, we expect this year's exports are expected to achieve million-dollar. Company is Yi Li Kang Shou imitated manufacturers behalf, after you pass FDA certification and export, in favour of product price maintenance, some provinces can also apply differential pricing. Companies in the United States
tera gold, the European Union for more than more than 10 products certification, is expected this year, 2-3 a variety of approved new declaration of May 6-7 varieties. Surgical anesthetics each year to speed development of 50% of the company, future growth is expected to remain.
Contrast last year to grow at a rate of 100%, 60% per cent growth is expected this year, also high speed development in the future. Profit forecasts and investment company is a benchmark for chemical pharmaceutical enterprises in China. Eric such as celecoxib, and ARPANET for the listing of new drugs improve valuations right beauty careMicrophones
tera power leveling, for the gonow, iodine Lexar alcohol generic drug promotion on the basis of last year, this year is expected to merchant, and ARPANET for the broad market space. We expect companies 12-14 EPS by $ 0.96/1.19/1.48 respectively (2011 EPS at $ 0.78), in accordance with the 2012 times forward earnings, target price of $ 33.6, maintained "Buy "rating. Risk drug price risk, risks of research and development of new drugs.
Others:
No comments:
Post a Comment